Welcome to our dedicated page for Movano SEC filings (Ticker: MOVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the path from prototype to FDA clearance can feel overwhelming when Movano Inc.’s disclosures stretch over hundreds of pages of technical jargon. Whether you’re watching the Evie Ring’s clinical milestones or simply need R&D burn-rate figures, Stock Titan’s AI turns dense paragraphs into clear takeaways, making Movano Inc. SEC filings explained simply a reality.
Need the details fast? Our dashboard streams every document the moment it lands on EDGAR—from a Movano Inc. quarterly earnings report 10-Q filing that breaks down sensor R&D costs, to an Movano Inc. 8-K material events explained summary covering fresh trial data. Curious about leadership confidence? We surface Movano Inc. insider trading Form 4 transactions and send real-time alerts for each Movano Inc. Form 4 insider transactions real-time update. Want the big picture without wading through footnotes? Click the AI summary beside any Movano Inc. annual report 10-K simplified or drill into the Movano Inc. proxy statement executive compensation tables in seconds.
Professionals use these insights to:
- Compare cash runway across quarters with Movano Inc. earnings report filing analysis
- Monitor FDA-related milestones disclosed in 8-Ks
- Spot patterns in Movano Inc. executive stock transactions Form 4 ahead of clinical announcements
Movano Inc. director Emily Fairbairn received a grant of 31,028 restricted stock units (RSUs) on
The filing documents a routine equity-based compensation transaction for a director rather than an open-market sale or purchase. The award replaces cash fees with equity, increasing the reporting person's holdings and aligning compensation with share ownership while not showing any cash consideration in the reported transaction.
Movano Inc. filed an 8-K disclosing a corporate action dated
The filing text provided here does not state the content of the amendment (for example, changes to authorized shares, classes, or rights), nor does it include financial metrics, transaction terms, or forward-looking statements. Because the filing references an amendment and a contemporaneous press release, investors should review the actual amendment text and the press release for details on what corporate terms changed and any stated rationale or effects on equity structure.
Movano Inc. director Wirk Shaheen received a grant of 20,685 restricted stock units (RSUs) under the company's Omnibus Incentive Plan as payment in lieu of directors' fees for the period
Movano Inc. director Brian Cullinan received a grant of 33,096 restricted stock units (RSUs) on 10/03/2025 that were issued in lieu of directors' fees for the period October 1, 2025 to December 31, 2025. The RSUs carry a reported price of $0 and the filing shows 151,452 RSUs or shares beneficially owned by the reporting person following the award. The Form 4 was signed on 10/07/2025 by an attorney-in-fact.
The transaction is recorded as an award under the company's Omnibus Incentive Plan and increases the director's reported beneficial ownership. No cash purchase or sale price is reported because these RSUs were granted in lieu of cash fees.
Movano Inc. director Ruben Caballero received a grant of 20,685 restricted stock units (RSUs) under the company Omnibus Incentive Plan in lieu of directors' fees for the period
Movano Inc. director and Chief Executive Officer John Mastrototaro received a grant of 165,484 restricted stock units (RSUs) on
This disclosure shows executive compensation was partly paid in equity for the stated quarter, which directly increases insider holdings and aligns pay with shareholder equity rather than cash salary for the specified period.
Jeremy Cogan, Chief Financial Officer and a director of Movano Inc. (MOVE), reported a grant of 134,456 restricted stock units (RSUs) received on